Phase I Study of IGM-8444 as a Single Agent and in Combination in Subjects With Relapsed and/or Refractory Solid Cancers
Status:
Recruiting
Trial end date:
2023-10-01
Target enrollment:
Participant gender:
Summary
This study is a first-in-human, Phase 1, multicenter, open-label study to determine the
safety, tolerability and pharmacokinetics of IGM-8444 as a single agent and in combination in
subjects with relapsed and/or refractory solid cancers